Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Current Deferred Revenue: 2016-2024

Historic Current Deferred Revenue for Wave Life Sciences (WVE) over the last 9 years, with Dec 2024 value amounting to $66.0 million.

  • Wave Life Sciences' Current Deferred Revenue fell 65.77% to $46.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year decrease of 65.77%. This contributed to the annual value of $66.0 million for FY2024, which is 56.04% down from last year.
  • Latest data reveals that Wave Life Sciences reported Current Deferred Revenue of $66.0 million as of FY2024, which was down 56.04% from $150.1 million recorded in FY2023.
  • In the past 5 years, Wave Life Sciences' Current Deferred Revenue registered a high of $150.1 million during FY2023, and its lowest value of $31.6 million during FY2022.
  • Its 3-year average for Current Deferred Revenue is $82.5 million, with a median of $66.0 million in 2024.
  • Per our database at Business Quant, Wave Life Sciences' Current Deferred Revenue tumbled by 59.48% in 2021 and then spiked by 375.50% in 2023.
  • Wave Life Sciences' Current Deferred Revenue (Yearly) stood at $91.6 million in 2020, then tumbled by 59.48% to $37.1 million in 2021, then declined by 14.93% to $31.6 million in 2022, then skyrocketed by 375.50% to $150.1 million in 2023, then crashed by 56.04% to $66.0 million in 2024.